Skip to main content

Advertisement

SpringerLink
Log in

A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial–mesenchymal transition in cancer

  • Original Article
  • Published:
Oncogene Submit manuscript

Abstract

Epithelial–mesenchymal transition (EMT) is an important biological process that has been implicated in cancer metastasis. Epithelial cell adhesion molecule (EpCAM) is expressed at the basolateral membrane of most normal epithelial cells but is overexpressed in many epithelial cancers. In our studies on the role of EpCAM in cancer biology, we observed that EpCAM expression is decreased in mesenchymal-like primary cancer specimens in vivo and following induction of EMT in cancer cell lines in vitro. Extracellular signal-related kinase (ERK) is a key regulator of EMT. We observed that EpCAM expression is decreased with activation of the ERK pathway in primary cancer specimens in vivo and in cancer cell lines in vitro. In experimental models, growth factor stimulation and/or oncogene-induced ERK2 activation suppressed EpCAM expression, whereas genetic or pharmacological inhibition of the ERK pathway restored EpCAM expression. In detailed studies of the EpCAM promoter region, we observed that ERK2 suppresses EpCAM transcription directly by binding to a consensus ERK2-binding site in the EpCAM promoter and indirectly through activation of EMT-associated transcription factors SNAI1, SNAI2, TWIST1 and ZEB1, which bind to E-box sites in the EpCAM promoter. Surprisingly, EpCAM appears to modulate ERK activity. Using multiple cell lines, we demonstrated that specific ablation of EpCAM resulted in increased ERK pathway activity and SNAI2 expression, migration and invasion, whereas forced expression of EpCAM resulted in decreased ERK pathway activity and SNAI2 expression, migration and invasion. These observations provide important insights into the regulation of EpCAM expression during EMT, demonstrate an unexpected role for EpCAM in the regulation of ERK and define a novel double-negative feedback loop between EpCAM and ERK that contributes to the regulation of EMT. These studies have important translational implications as both EpCAM and ERK are currently being targeted in human clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Klymkowsky MW, Savagner P . Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 2009; 174: 1588–1593.

    Article  CAS  Google Scholar 

  2. Polyak K, Weinberg RA . Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265–273.

    Article  CAS  Google Scholar 

  3. Thiery JP, Acloque H, Huang RY, Nieto MA . Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871–890.

    Article  CAS  Google Scholar 

  4. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704–715.

    Article  CAS  Google Scholar 

  5. Shin J, Yang J, Lee J, Baek KH . Depletion of ERK2 but not ERK1 abrogates oncogenic Ras-induced senescence. Cell Signal 2013; 25: 2540–2547.

    Article  CAS  Google Scholar 

  6. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J . ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Mol Cell 2010; 38: 114–127.

    Article  CAS  Google Scholar 

  7. Brabletz S, Brabletz T . The ZEB/miR-200 feedback loop—a motor of cellular plasticity in development and cancer? EMBO Rep 2010; 11: 670–677.

    Article  CAS  Google Scholar 

  8. Feldman S, Krishnamurthy S, Gillanders W, Gittleman M, Beitsch PD, Young PR et al. A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer 2011; 117: 2599–2607.

    Article  CAS  Google Scholar 

  9. Armstrong A, Eck SL . EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003; 2: 320–326.

    Article  CAS  Google Scholar 

  10. Munz M, Murr A, Kvesic M, Rau D, Mangold S, Pflanz S et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int 2010; 10: 44.

    Article  Google Scholar 

  11. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781–791.

    Article  CAS  Google Scholar 

  12. Osta WA, Chen Y, Mikhitarian K, Mitas M, Salem M, Hannun YA et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004; 64: 5818–5824.

    Article  CAS  Google Scholar 

  13. Sankpal NV, Willman MW, Fleming TP, Mayfield JD, Gillanders WE . Transcriptional repression of epithelial cell adhesion molecule contributes to p53 control of breast cancer invasion. Cancer Res 2009; 69: 753–757.

    Article  CAS  Google Scholar 

  14. Sankpal NV, Mayfield JD, Willman MW, Fleming TP, Gillanders WE . Activator protein 1 (AP-1) contributes to EpCAM-dependent breast cancer invasion. Breast Cancer Res 2011; 13: R124.

    Article  CAS  Google Scholar 

  15. Sankpal NV, Fleming TP, Gillanders WE . EpCAM modulates NF-kappaB signaling and interleukin-8 expression in breast cancer. Mol Cancer Res 2013; 11: 418–426.

    Article  CAS  Google Scholar 

  16. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162–171.

    Article  CAS  Google Scholar 

  17. Cheng JC, Chang HM, Leung PC . Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene 2013; 32: 1041–1049.

    Article  CAS  Google Scholar 

  18. Zhang K, Corsa CA, Ponik SM, Prior JL, Piwnica-Worms D, Eliceiri KW et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. Nat Cell Biol 2013; 15: 677–687.

    Article  CAS  Google Scholar 

  19. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 2013; 24: 466–480.

    Article  CAS  Google Scholar 

  20. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 2013; 19: 279–290.

    Article  CAS  Google Scholar 

  21. Gao J, Yan Q, Wang J, Liu S, Yang X . Epithelial-to-mesenchymal transition induced by TGF-beta1 is mediated by AP1-dependent EpCAM expression in MCF-7 cells. J Cell Physiol 2015; 230: 775–782.

    Article  CAS  Google Scholar 

  22. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009; 69: 2887–2895.

    Article  CAS  Google Scholar 

  23. Ye X, Tam WL, Shibue T, Kaygusuz Y, Reinhardt F, Ng Eaton E et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015; 525: 256–260.

    Article  CAS  Google Scholar 

  24. Lyons JG, Patel V, Roue NC, Fok SY, Soon LL, Halliday GM et al. Snail up-regulates proinflammatory mediators and inhibits differentiation in oral keratinocytes. Cancer Res 2008; 68: 4525–4530.

    Article  CAS  Google Scholar 

  25. Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD et al. ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett 2011; 300: 66–78.

    Article  CAS  Google Scholar 

  26. Vannier C, Mock K, Brabletz T, Driever W . Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion molecule) expression to control cell behavior in early zebrafish development. J Biol Chem 2013; 288: 18643–18659.

    Article  CAS  Google Scholar 

  27. Massoner P, Thomm T, Mack B, Untergasser G, Martowicz A, Bobowski K et al. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205. Br J Cancer 2014; 111: 955–964.

    Article  CAS  Google Scholar 

  28. Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 2012; 11: 710–719.

    Article  CAS  Google Scholar 

  29. Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 2006; 66: 7466–7472.

    Article  CAS  Google Scholar 

  30. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.

    Article  Google Scholar 

  31. Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL . TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 2011; 71: 4707–4719.

    Article  CAS  Google Scholar 

  32. Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010; 70: 2264–2273.

    Article  CAS  Google Scholar 

  33. Hu S, Xie Z, Onishi A, Yu X, Jiang L, Lin J et al. Profiling the human protein-DNA interactome reveals ERK2 as a transcriptional repressor of interferon signaling. Cell 2009; 139: 610–622.

    Article  CAS  Google Scholar 

  34. Grotegut S, von Schweinitz D, Christofori G, Lehembre F . Hepatocyte growth factor induces cell scattering through MAPK/Egr-1-mediated upregulation of Snail. EMBO J 2006; 25: 3534–3545.

    Article  CAS  Google Scholar 

  35. Hajra KM, Chen DY, Fearon ER . The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002; 62: 1613–1618.

    CAS  PubMed  Google Scholar 

  36. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes. Proc Natl Acad Sci USA 2010; 107: 15449–15454.

    Article  CAS  Google Scholar 

  37. Zhang P, Sun Y, Ma L . ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 2015; 14: 481–487.

    Article  CAS  Google Scholar 

  38. Kusewitt DF, Choi C, Newkirk KM, Leroy P, Li Y, Chavez MG et al. Slug/Snai2 is a downstream mediator of epidermal growth factor receptor-stimulated reepithelialization. J Invest Dermatol 2009; 129: 491–495.

    Article  CAS  Google Scholar 

  39. Maghzal N, Kayali HA, Rohani N, Kajava AV, Fagotto F . EpCAM controls actomyosin contractility and cell adhesion by direct inhibition of PKC. Dev Cell 2013; 27: 263–277.

    Article  CAS  Google Scholar 

  40. Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y et al. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 2012; 26: 1582–1592.

    Article  CAS  Google Scholar 

  41. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015; 527: 472–476.

    Article  CAS  Google Scholar 

  42. Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741–4751.

    Article  CAS  Google Scholar 

  43. Zheng X, Carstens JL, Kim J, Scheible M, Kaye J, Sugimoto H et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527: 525–530.

    Article  CAS  Google Scholar 

  44. Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15: 178–196.

    Article  CAS  Google Scholar 

  45. Carlson SM, Chouinard CR, Labadorf A, Lam CJ, Schmelzle K, Fraenkel E et al. Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3. Sci Signal 2011; 4: rs11.

    Article  Google Scholar 

  46. Courcelles M, Fremin C, Voisin L, Lemieux S, Meloche S, Thibault P . Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions. Mol Syst Biol 2013; 9: 669.

    Article  CAS  Google Scholar 

  47. Roskoski R Jr . ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012; 66: 105–143.

    Article  CAS  Google Scholar 

  48. Munz M, Baeuerle PA, Gires O . The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69: 5627–5629.

    Article  CAS  Google Scholar 

  49. Eberlein C, Rooney C, Ross SJ, Farren M, Weir HM, Barry ST . E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin alphavbeta6 and maintained through TGFbeta signalling. Oncogene 2014; 34: 704–716.

    Article  Google Scholar 

  50. Soysal SD, Muenst S, Barbie T, Fleming T, Gao F, Spizzo G et al. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer. Br J Cancer 2013; 108: 1480–1487.

    Article  CAS  Google Scholar 

  51. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH . Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005; 92: 1767–1772.

    Article  CAS  Google Scholar 

  52. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004; 86: 207–213.

    Article  CAS  Google Scholar 

  53. Yang X, Lin X, Zhong X, Kaur S, Li N, Liang S et al. Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 2010; 70: 9463–9472.

    Article  CAS  Google Scholar 

  54. Shi L, Jackstadt R, Siemens H, Li H, Kirchner T, Hermeking H . p53-induced miR-15a/16-1 and AP4 form a double-negative feedback loop to regulate epithelial-mesenchymal transition and metastasis in colorectal cancer. Cancer Res 2014; 74: 532–542.

    Article  CAS  Google Scholar 

  55. Siemens H, Jackstadt R, Hunten S, Kaller M, Menssen A, Gotz U et al. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011; 10: 4256–4271.

    Article  CAS  Google Scholar 

  56. Bracken CP, Gregory PA, Kolesnikoff N, Bert AG, Wang J, Shannon MF et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008; 68: 7846–7854.

    Article  CAS  Google Scholar 

  57. Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2014; 2: 78–91.

    Article  CAS  Google Scholar 

  58. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA . Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 2008; 68: 3645–3654.

    Article  CAS  Google Scholar 

  59. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013; 4: 1116–1130.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr Kerry Kornfeld, Dr Jason Weber and Dr Gregory Longmore for reviewing the manuscript and providing valuable advice. This work was supported by a grant from Susan G Komen for the Cure (BCTR0707917) and Siteman Cancer Center fund (P30CA91842).

Author information

Authors and Affiliations

  1. Department of Surgery, Washington University School of Medicine, St Louis, MO, USA

    N V Sankpal, T P Fleming, P K Sharma, H J Wiedner & W E Gillanders

  2. Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA

    W E Gillanders

Authors
  1. N V Sankpal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T P Fleming
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P K Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H J Wiedner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W E Gillanders
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W E Gillanders.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sankpal, N., Fleming, T., Sharma, P. et al. A double-negative feedback loop between EpCAM and ERK contributes to the regulation of epithelial–mesenchymal transition in cancer. Oncogene 36, 3706–3717 (2017). https://doi.org/10.1038/onc.2016.504

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2016.504

  • Springer Nature Limited

This article is cited by

Search

Navigation